Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer
YUJI HAYASHI, HIROYUKI TAKEI, SATOSHI NOZU, YOSHIHIRO TOCHIGI, AKIHIRO ICHIKAWA, NAOKI KOBAYASHI, MASAFUMI KUROSUMI, KENICHI INOUE, TAKASHI YOSHIDA, SHIGENORI E. NAGAI, HANAKO OBA, TOSHIO TABEI, JUN HORIGUCHI and IZUMI TAKEYOSHI
Oncology Letters 5: 83–89, 2013; DOI: 10.3892/ol.2012.1004
After the publication of the article, the authors noted that they had made an error regarding certain data in their manuscript. The error relates to the calculations made in Table IV.
Table VI.
Presence or absence of residual DCIS and MRI diagnoses.
| Residual DCIS (%)
|
|||
|---|---|---|---|
| Response | Absence | Presence | Total (%) |
| cCR | 36 (36.7) | 8 (8.2) | 44 (44.9) |
| Residual tumor | 30 (30.6) | 24 (24.5) | 54 (55.1) |
| Total | 66 (67.3) | 32 (32.7) | 98 (100.0) |
P=0.0058. cCR, clinical complete response; DCIS, ductal carcinoma in situ; MRI, magnetic resonance imaging.
On page 88 of our article, in the left-handed column, we identified an erroneous statistical result with respect to the percentages calculated in Table IV. Please see the corrected table below.